Fig. 1.

Overall survival and anti-tumor efficacy with MVA-BN-HER2 immunotherapy and CTLA-4 blockade. a Kaplan–Meier survival curves from the combined results of three independent studies. The median overall survival in control mice (30 days) was significantly extended with anti-CTLA-4 treatment (35 days, **p < 0.01), MVA-BN-HER2 treatment (49.5 days, ***p < 0.001), and MVA-BN-HER2+ anti-CTLA-4 combination therapy (>100 days, ***p < 0.001). A log-rank test with Bonferroni correction was used to determine significance between groups. b Representative lungs from each group harvested at day 25 were stained with Trypan Blue. Healthy lung tissue appears blue, while tumors appear red and white. Scale bar 1 cm. c Lung weights from treated mice on day 25 compared to naïve mice. A one-way ANOVA with Dunnett’s multiple comparisons test was used to determine significance between groups, ****p < 0.0001